Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced proposed amendments to its Articles of Association to align with new guidelines from the China Securities Regulatory Commission and meet its governance needs. These amendments require shareholder approval at the upcoming general meeting, indicating a strategic move to enhance corporate governance and regulatory compliance.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$300.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company is listed on the Hong Kong Stock Exchange and focuses on developing and manufacturing biopharmaceutical products.
Average Trading Volume: 703,281
Technical Sentiment Signal: Buy
Current Market Cap: HK$71.59B
See more data about 6990 stock on TipRanks’ Stock Analysis page.